Compare Davita Inc (DVA) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nomura Holdings Inc — how do they compare? Davita Inc trades at $179.93 (market cap $11.38B), while Nomura Holdings Inc trades at $9.93 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 2.5× Davita Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | NMR | |
|---|---|---|
Market Cap | $11.38B | $28.46B |
Sector | Health | Financials |
52-Week High | $240.96 | $10.04 |
52-Week Low | $103.87 | $6.73 |
Enterprise Value | $24.10B | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.25, down 1.87% amid mixed signals. The stock shows strong earnings momentum with three consecutive quarterly beats (Q4 2025-Q2 2026) but faces margin pressure. Technical indicators are conflicted with a bullish overall signal but bearish moving averages. Revenue growth remains steady, climbing from $11.6B in 2022 to $13.6B in 2025, though net income margin fluctuated between 4.82% and 7.3% over the same period.
The outlook is cautiously optimistic with a $232.25 consensus price target offering 29% upside. Key risks include reimbursement pressure and high debt levels (debt-to-asset ratio of 65.55% in 2025). Analyst sentiment leans neutral (56.52% Hold) despite recent earnings strength, reflecting concerns about payer mix and margin sustainability.
Nomura Holdings (NMR) trades at $9.905, up 0.87% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.59, net income margin of 20.4%, and robust revenue growth to $1.66 trillion in 2025. Recent Q2 2026 earnings beat expectations, and news highlights momentum in wholesale and wealth management divisions.
Outlook remains positive due to earnings strength and undervaluation, but risks include volatile cash flows and rising debt-to-asset ratio. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
